151 related articles for article (PubMed ID: 36842160)
1. Prospective role of 3βHSD1 in prostate cancer precision medicine.
Zhuang Q; Huang S; Li Z
Prostate; 2023 May; 83(7):619-627. PubMed ID: 36842160
[TBL] [Abstract][Full Text] [Related]
2. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.
Mei Z; Yang T; Liu Y; Gao Y; Hou Z; Zhuang Q; He D; Zhang X; Tan Q; Zhu X; Qin Y; Chen X; Xu C; Bian C; Wang X; Wang C; Wu D; Huang S; Li Z
Cell Rep Med; 2022 May; 3(5):100608. PubMed ID: 35584629
[TBL] [Abstract][Full Text] [Related]
3. Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression.
Qin L; Berk M; Chung YM; Cui D; Zhu Z; Chakraborty AA; Sharifi N
Cell Rep; 2024 Jan; 43(1):113575. PubMed ID: 38181788
[TBL] [Abstract][Full Text] [Related]
4. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
[TBL] [Abstract][Full Text] [Related]
5. Approaches to assessing 3β-hydroxysteroid dehydrogenase-1.
Alyamani M; McManus J; Patel M; Sharifi N
Methods Enzymol; 2023; 689():89-119. PubMed ID: 37802584
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.
Ganguly S; Lone Z; Muskara A; Imamura J; Hardaway A; Patel M; Berk M; Smile TD; Davicioni E; Stephans KL; Ciezki J; Weight CJ; Gupta S; Reddy CA; Tendulkar RD; Chakraborty AA; Klein EA; Sharifi N; Mian OY
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37966114
[TBL] [Abstract][Full Text] [Related]
7. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
Alyamani M; Emamekhoo H; Park S; Taylor J; Almassi N; Upadhyay S; Tyler A; Berk MP; Hu B; Hwang TH; Figg WD; Peer CJ; Chien C; Koshkin VS; Mendiratta P; Grivas P; Rini B; Garcia J; Auchus RJ; Sharifi N
J Clin Invest; 2018 Aug; 128(8):3333-3340. PubMed ID: 29939161
[TBL] [Abstract][Full Text] [Related]
8. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
[TBL] [Abstract][Full Text] [Related]
9. Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer.
Shiota M; Endo S; Tsukahara S; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38688318
[TBL] [Abstract][Full Text] [Related]
10. Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer.
Zhang X; Wang Z; Huang S; He D; Yan W; Zhuang Q; Wang Z; Wang C; Tan Q; Liu Z; Yang T; Liu Y; Ren R; Li J; Butler W; Tang H; Wei GH; Li X; Wu D; Li Z
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 38099500
[TBL] [Abstract][Full Text] [Related]
11. HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.
Han FF; Ren LL; Xuan LL; Lv YL; Liu H; Gong LL; An ZL; Liu LH
Cancer Chemother Pharmacol; 2021 Jan; 87(1):103-112. PubMed ID: 33141329
[TBL] [Abstract][Full Text] [Related]
12. BMX controls 3βHSD1 and sex steroid biosynthesis in cancer.
Li X; Berk M; Goins C; Alyamani M; Chung YM; Wang C; Patel M; Rathi N; Zhu Z; Willard B; Stauffer S; Klein E; Sharifi N
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647826
[TBL] [Abstract][Full Text] [Related]
13. A phosphorylation switch controls androgen biosynthesis in prostate cancer.
Qiu Y
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647834
[TBL] [Abstract][Full Text] [Related]
14. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer.
Hou Z; Huang S; Mei Z; Chen L; Guo J; Gao Y; Zhuang Q; Zhang X; Tan Q; Yang T; Liu Y; Chi Y; Qi L; Jiang T; Shao X; Wu Y; Xu X; Qin J; Ren R; Tang H; Wu D; Li Z
Cell Rep Med; 2022 Mar; 3(3):100561. PubMed ID: 35492874
[TBL] [Abstract][Full Text] [Related]
16. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC
Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
[TBL] [Abstract][Full Text] [Related]
18. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation.
Cui D; Li J; Zhu Z; Berk M; Hardaway A; McManus J; Chung YM; Alyamani M; Valle S; Tiwari R; Han B; Goudarzi M; Willard B; Sharifi N
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 37009898
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer.
Qin L; Chung YM; Berk M; Naelitz B; Zhu Z; Klein E; Chakraborty AA; Sharifi N
Cancer Res; 2022 Jul; 82(13):2417-2430. PubMed ID: 35536859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
